Definitive Healthcare Closes Public Stock Offering After Selling About $483 Million in Shares

Share, email, print, bookmark SOURCE reports.

In full transparency, the following is a press release submitted to SOURCE media, through its business wire service.

***

FRAMINGHAM – Definitive Healthcare Corp., a Framingham-based healthcare commercial intelligence, today, September 20, announced the closing of its previously announced initial public offering of 17,888,888 shares of its Class A common stock, which includes the full exercise by the underwriters of their option to purchase up to an additional 2,333,333 shares of its Class A common stock, at a public offering price of $27 per share.

Aggregate gross proceeds to Definitive Healthcare were approximately $483 million, before underwriting discounts, commissions, and estimated offering expenses.

Definitive Healthcare’s Class A common stock began trading on the Nasdaq Global Select Market under the ticker symbol “DH” on September 15, 2021.Goldman Sachs & Co. LLC and J.P. Morgan acted as lead joint book-running managers and representatives of the underwriters for the proposed offering. Morgan Stanley and Barclays acted as joint book-running managers and are also representatives of the underwriters for the proposed offering.

Credit Suisse and Deutsche Bank Securities acted as book-runners for the proposed offering. Canaccord Genuity, Raymond James, Stifel, Drexel Hamilton and Loop Capital Markets acted as co-managers.

The offering was made only by means of a prospectus.

A copy of the final prospectus relating to the proposed offering may be obtained from the SEC at www.sec.gov or from: Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204 or by email at prospectuseq_fi@jpmorganchase.com; Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 718-1649 or by email at prospectus@morganstanley.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (888) 603-5847 or by at email at barclaysprospectus@broadridge.com.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 14, 2021.

editor

email: editor@FraminghamSource.com call or text at 508-315-7176